70 related articles for article (PubMed ID: 20185912)
1. Gene expression profile of colon cancer cell lines treated with SN-38.
Wallin A; Francis P; Nilbert M; Svanvik J; Sun XF
Chemotherapy; 2010; 56(1):17-25. PubMed ID: 20185912
[TBL] [Abstract][Full Text] [Related]
2. Anticancer effect of SN-38 on colon cancer cell lines with different metastatic potential.
Wallin A; Svanvik J; Holmlund B; Ferreud L; Sun XF
Oncol Rep; 2008 Jun; 19(6):1493-8. PubMed ID: 18497955
[TBL] [Abstract][Full Text] [Related]
3. [Analysis of gene expression patterns in an irinotecan-resistance colon cancer cell by cDNA microarray].
Chen X; Chen XZ; Liu M; Lang N; Tang QL; Chen J; Zhao XF; Bi F
Sichuan Da Xue Xue Bao Yi Xue Ban; 2011 Jan; 42(1):15-8, 36. PubMed ID: 21355292
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin.
Mariadason JM; Arango D; Shi Q; Wilson AJ; Corner GA; Nicholas C; Aranes MJ; Lesser M; Schwartz EL; Augenlicht LH
Cancer Res; 2003 Dec; 63(24):8791-812. PubMed ID: 14695196
[TBL] [Abstract][Full Text] [Related]
5. Irinotecan induces steroid and xenobiotic receptor (SXR) signaling to detoxification pathway in colon cancer cells.
Basseville A; Preisser L; de Carné Trécesson S; Boisdron-Celle M; Gamelin E; Coqueret O; Morel A
Mol Cancer; 2011 Jul; 10():80. PubMed ID: 21733184
[TBL] [Abstract][Full Text] [Related]
6. Altered expression of cell proliferation-related and interferon-stimulated genes in colon cancer cells resistant to SN38.
Gongora C; Candeil L; Vezzio N; Copois V; Denis V; Breil C; Molina F; Fraslon C; Conseiller E; Pau B; Martineau P; Del Rio M
Cancer Biol Ther; 2008 Jun; 7(6):822-32. PubMed ID: 18340113
[TBL] [Abstract][Full Text] [Related]
7. Schlafen-11 sensitizes colorectal carcinoma cells to irinotecan.
Tian L; Song S; Liu X; Wang Y; Xu X; Hu Y; Xu J
Anticancer Drugs; 2014 Nov; 25(10):1175-81. PubMed ID: 25089570
[TBL] [Abstract][Full Text] [Related]
8. The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38.
LaBonte MJ; Manegold PC; Wilson PM; Fazzone W; Louie SG; Lenz HJ; Ladner RD
Int J Cancer; 2009 Dec; 125(12):2957-69. PubMed ID: 19536776
[TBL] [Abstract][Full Text] [Related]
9. Schedule-dependent cytotoxicity of SN-38 in p53 wild-type and mutant colon adenocarcinoma cell lines.
te Poele RH; Joel SP
Br J Cancer; 1999 Dec; 81(8):1285-93. PubMed ID: 10604724
[TBL] [Abstract][Full Text] [Related]
10. Irinotecan changes gene expression in the small intestine of the rat with breast cancer.
Bowen JM; Gibson RJ; Cummins AG; Tyskin A; Keefe DM
Cancer Chemother Pharmacol; 2007 Feb; 59(3):337-48. PubMed ID: 16799812
[TBL] [Abstract][Full Text] [Related]
11. Identification of metastasis-associated genes by transcriptional profiling of metastatic versus non-metastatic colon cancer cell lines.
De Lange R; Burtscher H; Jarsch M; Weidle UH
Anticancer Res; 2001; 21(4A):2329-39. PubMed ID: 11724290
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional regulation of mitotic genes by camptothecin-induced DNA damage: microarray analysis of dose- and time-dependent effects.
Zhou Y; Gwadry FG; Reinhold WC; Miller LD; Smith LH; Scherf U; Liu ET; Kohn KW; Pommier Y; Weinstein JN
Cancer Res; 2002 Mar; 62(6):1688-95. PubMed ID: 11912141
[TBL] [Abstract][Full Text] [Related]
13. in vitro synergistic antitumor activity of a combination of 5-fluorouracil and irinotecan in human colon cancer.
Inoue Y; Tanaka K; Hiro J; Yoshiyama S; Toiyama Y; Eguchi T; Miki C; Kusunoki M
Int J Oncol; 2006 Feb; 28(2):479-86. PubMed ID: 16391804
[TBL] [Abstract][Full Text] [Related]
14. Clinical determinants of response to irinotecan-based therapy derived from cell line models.
Allen WL; Coyle VM; Jithesh PV; Proutski I; Stevenson L; Fenning C; Longley DB; Wilson RH; Gordon M; Lenz HJ; Johnston PG
Clin Cancer Res; 2008 Oct; 14(20):6647-55. PubMed ID: 18927307
[TBL] [Abstract][Full Text] [Related]
15. Prediction of novel target genes and pathways involved in irinotecan-resistant colorectal cancer.
Makondi PT; Chu CM; Wei PL; Chang YJ
PLoS One; 2017; 12(7):e0180616. PubMed ID: 28749961
[TBL] [Abstract][Full Text] [Related]
16. CPT-11 (SN-38) chemotherapy may be selectively applicable to biliary tract cancer with low hMLH1 expression.
Sato K; Kitajima Y; Kohya N; Koga Y; Ohtaka K; Miyazaki K
Anticancer Res; 2007; 27(2):865-72. PubMed ID: 17465213
[TBL] [Abstract][Full Text] [Related]
17. [Combination with SN-38 on human colon cancer LoVo cells].
Wang Y; Xu JM; Xu QZ; Zhou PK; Song ST
Zhonghua Zhong Liu Za Zhi; 2009 Oct; 31(10):746-851. PubMed ID: 20021826
[TBL] [Abstract][Full Text] [Related]
18. Camptothecin and its analog SN-38, the active metabolite of irinotecan, inhibit binding of the transcriptional regulator and oncoprotein FUBP1 to its DNA target sequence FUSE.
Khageh Hosseini S; Kolterer S; Steiner M; von Manstein V; Gerlach K; Trojan J; Waidmann O; Zeuzem S; Schulze JO; Hahn S; Steinhilber D; Gatterdam V; Tampé R; Biondi RM; Proschak E; Zörnig M
Biochem Pharmacol; 2017 Dec; 146():53-62. PubMed ID: 29031818
[TBL] [Abstract][Full Text] [Related]
19. Short hairpin RNAs targeting Bcl-xL modulate senescence and apoptosis following SN-38 and irinotecan exposure in a colon cancer model.
Guichard SM; Hua ML; Kang P; Macpherson JS; Jodrell DI
Cancer Chemother Pharmacol; 2007 Oct; 60(5):651-60. PubMed ID: 17273826
[TBL] [Abstract][Full Text] [Related]
20. P53 status plays no role in radiosensitizing effects of SN-38, a camptothecin derivative.
Xie X; Sasai K; Shibuya K; Tachiiri S; Nihei K; Ohnishi T; Hiraoka M
Cancer Chemother Pharmacol; 2000; 45(5):362-8. PubMed ID: 10803918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
